register

News & Trends - MedTech & Diagnostics

Australia’s largest cancer care provider extends international footprint

Health Industry Hub | August 23, 2023 |

MedTech & Diagnostics News: Australia’s largest integrated cancer care provider, Icon Group, is joining forces with Nuffield Health, United Kingdom’s largest healthcare charity. Backed by the strategic investment of private equity firm EQT, this dynamic partnership is poised to redefine the standards of oncology care and deliver unparalleled patient experience.

Icon Group and Nuffield Health are embarking on a visionary venture aimed at providing top-tier oncology care that seamlessly combines clinical expertise with a world-class patient journey. This transformative alliance is set to kick off with a focus on advancing radiotherapy services – a pivotal aspect of modern cancer treatment.

Nuffield Health holds a distinguished record as the sole UK-wide independent hospital provider with all of its hospitals earning ‘Good’ or ‘Outstanding’ ratings from UK regulators. Their mission to deliver exceptional care within local communities mirrors Icon Group’s commitment to raising the bar for cancer treatment on a global scale. Having expanded its footprint to New Zealand, Singapore, Mainland China, and Hong Kong, Icon Group brings a wealth of experience and innovation to this collaboration.

Wouter Van den Brande, Chief Strategy and Development Officer of Nuffield Health, expressed the excitement surrounding the partnership. He said “Icon Group’s clinical expertise, values and investment strategy align closely with ours. We have a shared vision to deliver the best clinical outcomes to as many people as possible. We are working in partnership with Icon to explore how, together, we can meet the rising demand for cancer care in the UK. Our initial focus will be on how our patients can benefit from Icon’s world-leading expertise in radiotherapy.”

Mark Middleton, CEO of Icon Group, echoed the enthusiasm for the collaboration, saying “We’re thrilled to partner with Nuffield Health and work together to help tackle the UK’s cancer burden and improve access to radiotherapy, across the region. Patient focused and clinician led, this partnership prioritises personalised treatment plans and access to cutting edge treatments to deliver the highest standards of care and improved outcome for patients.”

In the forthcoming months, Icon Group and Nuffield Health will join forces to usher in the inaugural phase of their transformative partnership, with details of the collaboration soon to be unveiled.

In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.


News & Trends - MedTech & Diagnostics

Policy paralysis: Private hospitals left to clean up the government’s mess on medical device reforms

Policy paralysis: Private hospitals left to clean up the government’s mess on medical device reforms

Health Industry Hub | April 17, 2025 |

Hospitals shouldn’t be forced to grovel to private health insurers to secure funding for essential, lifesaving medical devices. But thanks […]

More


News & Trends - Pharmaceuticals

Oncologists pioneer liquid biopsy-guided treatment in lung cancer

Oncologists pioneer liquid biopsy-guided treatment in lung cancer

Health Industry Hub | April 17, 2025 |

Lung cancer is Australia’s leading cause of cancer deaths. Local experts are set to lead a new frontier in personalised […]

More


Medical and Science

The high cost of record low research funding

The high cost of record low research funding

Health Industry Hub | April 17, 2025 |

Australia has delivered some of the world’s most transformative health and medical breakthroughs – the cochlear implant, the HPV vaccine, […]

More


News & Trends - Pharmaceuticals

UCB secures dermatology indication with first dual IL-17A/F inhibitor

UCB secures dermatology indication with first dual IL-17A/F inhibitor

Health Industry Hub | April 17, 2025 |

UCB’s IL-17A and IL-17F inhibitor has been added to the Australian Register of Therapeutic Goods (ARTG) for adults with moderate […]

More


This content is copyright protected. Please subscribe to gain access.